CBD in Switzerland
The Swiss market is different to many other markets, not simply due to its higher 1% THC limit in comparison to others but also due to flexible regulations around cultivation. This page contains all of our content that relates to Switzerland, including all of our detailed regulatory and market reports, our business and regulatory briefings, and all of our up-to-date trackers, databases and live alerts.
Business briefing
Regulatory briefing
More Regulatory briefingRegulatory reports
Medical and recreational cannabis – a global overview
10th May 2021
Charts and infographics
More Charts and infographicsRegulatory alerts roundup
CBD-Intel regulatory news in brief, 6th-12th March
12th March 2021
A more open and relaxed market in Switzerland
CBD is not a scheduled substance in Switzerland; its legality in the finished product depends on the intended use. Some peculiarities of the Swiss market make it noticeably different from other markets. The market can be considered more open in terms of availability of CBD products as regulations are very flexible and cultivation of hemp is not only permitted but products can also contain up to 1% of THC. Flowers are also widely available while other product categories that are popular in other markets are not as popular. This difference is probably related to the ease of production of the flowers and more traditional consumer preferences in the country.
Switzerland is launching a three-year trial period on the sale of cannabis for recreational use, meaning that in the biggest Swiss cities – in a controlled manner and under certain conditions – it will be possible to acquire and consume cannabis legally. Each city will develop its own project and the approved amendment to implement this pilot scheme is in its final stage. It is expected to enter into force in mid-2021.
